Xiatong Bio Secures Investment from a Fund Affiliated with a Leading Public Company, with Riemann Hypothesis as Exclusive Financial Advisor
ExoNeuglia
Developer of Stem Cell Therapeutics for the Nervous System
Riemann-Hypothesis
Boutique Investment Bank in the Biomedical Field
Founder Financing Review
Recalling this round of financing, Dr. Guo Ying, founder of Xiatong Biotech, stated, “Against the backdrop of the winter in biomedical financing, the rapid and efficient completion of this round was inseparable from our close collaboration with Riemann-Hypothesis.”
Riemann-Hypothesis demonstrated exceptional professionalism, a strong sense of responsibility, and high efficiency throughout every stage of the financing process. Leveraging its in-depth understanding of the project, Riemann-Hypothesis continuously refined its financing strategy, overcame numerous challenges, and ultimately secured successful deal closure.
"Most importantly, we highly appreciate the exclusive strategic partnership and fully managed operational model established between our two parties, which has saved us significant effort and allowed us to focus on R&D. We are deeply grateful for this and will continue to maintain a long-term strategic cooperation with Riemann-Hypothesis."
—— Dr. Guo Ying, Founder of Xiatong Biotech
Recently, Xiatong Biotech—the only integrated continuous technology platform in China that utilizes cell reprogramming and induced differentiation technologies to develop oligodendrocyte progenitor cells (OPCs) for the treatment of neurological diseases—announced that it has secured investment from a fund affiliated with a well-known listed company. This funding will accelerate investigator-initiated trials (IITs) and investigational new drug (IND) applications for its pipeline candidates targeting demyelinating diseases of the nervous system.Riemann-Hypothesis Serves as the Exclusive Financial Advisor for This Financing Round。
Xiatong Biology was established in July 2022. It is a highly applicable and innovative enterprise dedicated to the development of cell therapies via induced reprogramming pathways. The company ranks among the international leaders in establishing a closed-loop R&D process that integrates theory, technology, and manufacturing processes, particularly for neurological disorders caused by demyelination. Xiatong Biology was the first globally to demonstrate that exogenous oligodendrocyte progenitor cells (OPCs) can form myelin sheaths in vivo and has established commercial-scale, industrial-grade in vitro manufacturing technology for human-derived OPCs. Furthermore, the company has pioneered a method for generating induced neural stem cells (iNSCs) in a single step from peripheral blood mononuclear cells (PBMCs) through induction with transcription factors and small molecules. This approach ensures an abundant and unrestricted cell source, involves no embryonic stem cells throughout the entire process, and poses no ethical concerns or tumorigenic risks. The company independently controls all key technological and process links from starting cells to formulated drug products, with its manufacturing process having advanced to industrial-scale production. These advantages have been highly recognized by the investment community. The funds raised in this round will be primarily used to advance Investigator-Initiated Trials (IITs) and Investigational New Drug (IND) applications for pipeline candidates targeting demyelinating neurological diseases and other indications.
The company’s core team comprises top-tier R&D professionals from leading industrial and scientific institutions both in China and abroad, with a long-standing focus on basic research and technological development of cell-based drugs and therapies for neurological disorders. The founding team brings decades of experience in researching drugs and stem cell therapies for neurological diseases and is recognized as a pioneer in cellular therapy for demyelinating diseases. The industry translation team is highly experienced, having successfully advanced several CGT (Cell and Gene Therapy) products into clinical development. The company’s Scientific Advisory Board includes Nobel laureates and industry leaders, primarily specializing in neurological disorders and cell therapy.
Dr. Guo Ying, Founder of Xiatong BiologyStatement: We extend our deepest gratitude to the founding team for their sustained efforts, and to our investors for their steadfast support and trust. The successful completion of this financing round serves as a strong endorsement of Xiatong Biotechnology’s operational capabilities, as well as the developmental potential of its reprogramming-induced oligodendrocyte progenitor cell (OPC) technology and its one-step induction method for generating induced neural stem cells (iNSCs). Leveraging OPC-based therapies for hypomyelinating leukodystrophies and multiple sclerosis as an entry point, the company aims to progressively promote the widespread adoption of cell therapies in the field of neurological disorders. In doing so, we strive to realize our vision of “universal healthcare access and shared health” for biologics, while committing ourselves to becoming an international pioneer in the application of reprogramming technologies within regenerative neurology.
Dr. Li Chaoxing, Chairman of Riemann-Hypothesis, as the exclusive financial advisor for this financing round“Xiatong Bio is a highly distinctive biotechnology company specializing in cell therapy for neurological disorders, with profound expertise and strong competitive advantages particularly in the fields of oligodendrocytes and neurons. Leveraging its deep understanding of oligodendrocyte development and differentiation, the company has developed and optimized processes for the reprogramming and induced differentiation of oligodendrocyte precursor cells (OPCs), significantly reducing cell culture cycles and costs while greatly enhancing cell purity. Furthermore, Xiatong Bio has pioneered a one-step reprogramming technology that enables direct dedifferentiation and redifferentiation from peripheral blood mononuclear cells (PBMCs) to induced neural stem cells (iNSCs), bypassing the induced pluripotent stem cell (iPSC) stage. This approach mitigates the tumorigenic risks associated with iPSCs and avoids potential ethical concerns. Currently, the cell therapy sector is entering a phase of standardized development driven by supportive policies, and cell therapy drugs are a key industry encouraged by national priorities. We look forward to the early market launch of Xiatong Bio’s products to benefit patients with neurological disorders worldwide.”
# On the Riemann Hypothesis
Riemann-Hypothesis, founded by Dr. Li Chaoxing upon his return to China from the United States, is an industrial investment bank focused on “institutionalized” industrial innovation across the full lifecycle of the life sciences sector. Upholding its original mission of collaborating with scientist-entrepreneurs who possess global vision, profound insights, and ambitious aspirations, Riemann-Hypothesis is committed to providing investment incubation and “fully managed” industrial investment banking services for groundbreaking and pioneering biomedical projects worldwide. It has fully established its proprietary “institutionalized” empowerment system, breaking through the limitations of traditional technology transfer, venture capital investment, and boutique investment banking.